CHEMISTRY OF β-LACTAM SULTAMICILLIN AS A MUTUAL PRODRUG OF AMPICILLIN AND SULBACTAM WORKS AS AN AZABICYCLO[3.2.0]HEPTANE CARBOPENAM BIOPRECURSOR

Journal Title: World Journal of Pharmaceutical and life sciences - Year 2017, Vol 3, Issue 9

Abstract

A large number of therapeutic medications have undesirable properties that may generate pharmacological, pharmaceutical, or pharmacokinetic barriers in clinical drug applications. Metabolism of drugs by Phase-I & Phase-II metabolic pathways for possibility of active metabolites, which could in turn useful for rational designing of bioprecursor prodrugs of the active principle of interest. Prodrug is a substance which after administration is metabolized into a pharmacologically active drug. Actually Prodrug has least medicinal value in in-vitro/in-vivo but after biotransformation by metabolism in in-vivo it releases the active medicament. A drug is a substance which is a chemical entity, has definite structural skeleton, obtained by natural or synthetic or semisynthetic source, which can fit on bioreceptor platform having controlling capacity to control over the biochemical malfunction. Every drug is xenobiotic because it is coming from outer source (xeno) and active in biological unit (biotic). Prodrug is the precursor of drug which is made by derivatization of the same to enhance the bioavailability by pharmacokinetics, lipid solubility by partition coefficient and increase the physicochemical & biochemical parameters by pharmacodynamics. Prodrug is a precursor (forerunner) of a drug. A prodrug must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent. For example, sultamicillin is a prodrug. It is not active in its ingested form. It has to be broken down before becoming active as a drug. It is a compound that on administration undergoes chemical conversion by metabolic processes to yield active moieties of ampicillin and sulbactam. This is also is called as biotransformation which produces active drug for pharmacological response from prodrug which is inactive by itself.

Authors and Affiliations

Prof. Dr. Dhrubo Jyoti Sen

Keywords

Related Articles

MOTHER AND CHILD CARE THROUGH YOGA AND NATUROPATHY

Pregnancy is the process whereby the life of a baby begins in the mother’s womb and progresses up to the stage when it is safe to expose the baby to the outside world. Pregnancy is a very precious and important event in...

THE EFFECT ON TRACE ELEMENTS OF BRAIN AND LIVER OF RAT EXPOSED TO FLUORIDE

Fluoride is a naturally occurring toxic mineral present in drinking water. Fluoride can accumulate in the body, and it has been shown that continuous exposure to it causes damaging effects on body tissues such as liver,...

ESTIMATION OF HEPATITIS B SURFACE ANTIBODY (HBsAb) AMONG MEDICAL STUDENTS OF BINGHAM UNIVERSITY COLLEGE OF MEDICINE AND HEALTH SCIENCES, JOS

Background: As persistence hepatitis B virus infection has grave consequences and no satisfactory treatment is available for Medical students and health care professionals, saving themselves of this menace cannot be over...

PHARMACOVIGILANCE: PROCESS OF DETECTION, ASSESSMENT, UNDERSTANDING AND PREVENTION OF ADVERSE EFFECTS: A REVIEW

Pharmacovigilance is synonymous with drug safety. Pharmacovigilance looks for the adverse effects of drugs after the event whilst the phrase 'drug safety' implies a positive approach before any event, almost the reciproc...

REVIEW: ECONOMIC VALUATION TECHNIQUES FOR CONSERVATION OF NATURAL RESOURCES AND WATERSHED MANAGEMENT

One of the objectives of conservation of natural resources is to strive for environmental sustainability for the benefit of the entire community. Achieving this goal means maximizing the total economic value of a conserv...

Download PDF file
  • EP ID EP649600
  • DOI -
  • Views 167
  • Downloads 0

How To Cite

Prof. Dr. Dhrubo Jyoti Sen (2017). CHEMISTRY OF β-LACTAM SULTAMICILLIN AS A MUTUAL PRODRUG OF AMPICILLIN AND SULBACTAM WORKS AS AN AZABICYCLO[3.2.0]HEPTANE CARBOPENAM BIOPRECURSOR. World Journal of Pharmaceutical and life sciences, 3(9), 132-139. https://europub.co.uk/articles/-A-649600